New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
16:23 EDTCYTXCytori Therapeutics places enrollment in ATHENA, ATHENA II trials on hold
Cytori Therapeutics has placed enrollment in the ATHENA and ATHENA II trials on clinical hold and therefore anticipates that it will not be possible to complete enrollment of the ATHENA I trial prior to the end of 2014 as previously anticipated. The decision to place the trials on hold was based on a safety review of reported cerebrovascular events. Symptoms occurred in three patients, of which two patients’ symptoms fully resolved within a short period of time and the third patient has had substantial resolution of symptoms. Such events had not been previously reported in Cytori’s other cardiovascular trials and appear to be related in part to the medical co-morbidities in the treated population and the complex nature of the procedures involved in the trial.
News For CYTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
11:55 EDTCYTXCytori Therapeutics management to meet with Roth Capital
Subscribe for More Information
January 22, 2015
11:27 EDTCYTXCytori Therapeutics management to meet with Roth Capital
Subscribe for More Information
January 20, 2015
16:25 EDTCYTXCytori says STAR trial will begin enrolling in 2015
Subscribe for More Information
08:40 EDTCYTXCytori Therapeutics price target raised to $6 from $3.50 at Roth Capital
Roth Capital increased its price target on Cytori after the company received final FDA approval for a clinical trial of its treatment for scleroderma., and the firm attended an event hosted by the company with a scleroderma expert. Roth says that the expert highlighted the unmet medical need in scleroderma as well its significant morbidity and mortality. The firm expects the company's visibility to improve this year, and it keeps a Buy rating on the stock.
January 16, 2015
12:20 EDTCYTXCytori Therapeutics price target raised to $6 from $3.50 at Roth Capital
Roth Capital raised its price target for Cytori Therapeutics to $6 and keeps a Buy rating on the name. The stock is rating up 3% to 46c.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use